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To investigate whether a relationship between chemotherapy-associated adverse events and treatment efficacy exists, we have
analysed the toxicity, objective response and survival data of 303 patients with advanced colorectal cancer. Patients were divided into
two groups: the first with beneficial effect (I, n¼245), and the second with progressive disease (II, n¼58). Differences in terms of
incidence rates, type and severity of adverse events were analysed with univariate and multivariate models. The median number of
side effects in group I was 6 vs 4 in group II (OR¼1.342; P¼0.0001). An inverse correlation between disease control and treatment
tolerance was confirmed when side effects were analysed according to severity and type of treatment-associated toxicities
(haematological: P¼0.0005 vs nonhaematological P¼0.0001). When median survival was analysed according to the number of
adverse events, it was 10 (95% CI, 3–7), 16 (14–18), and 18 (16–20) months in case of 0–1, 2–5, and X6 adverse events,
respectively (P¼0.01). In conclusion, the results of this analysis suggest that occurrence of side effects during chemotherapy in
advanced colorectal cancer is an independent and reliable prognostic indicator for response and survival.
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Colorectal cancer is one of the most common malignancies in the
western world (Landis et al, 1999). Nearly one-third of all patients
initially present with locally advanced, inoperable tumours and/or
distant metastases (Williams et al, 1995; Midgley and Kerr, 1999),
and approximately 50% of those having undergone potential
curative surgery will ultimately develop recurrent disease. Median
survival of these patients treated with best supportive care alone is
approximately 6 months (Scheithauer et al, 1993); if treated with
modern combination chemotherapy, median survival ranges from
17 to 21 months (Grothey et al, 2004). The effectiveness of
conventional intravenous 5-fluorouracil (FU) given with or with-
out biochemical modulators such as leucovorin (LV) or metho-
trexate, in fact, has been considerably improved with the recent
development of a number of new, promising anticancer agents.
These include the third generation 1,2-diaminocyclohexane-
platinum derivate oxaliplatin, and the topoisomerase I inhibitor
irinotecan. When combined with FU/LV or the oral FU prodrug
capecitabine, they seem to exert a synergistic effect which results in
major improvement in overall response rate and progression-free
survival, occasionally in overall survival (Grothey et al, 2004).
Potential prognostic markers determining response and/or
survival have been described in numerous studies, and include a
variety of clinical and laboratory parameters. In the largest series,
a multivariate analysis of 3825 patients treated with FU-based
chemotherapy, performance status, the number of metastatic sites,
alkaline phosphatase, and the leukocyte count were identified as
the most relevant parameters (Ko ¨hne et al, 2002).
As it concerns the relationship between toxicity incidence and
treatment efficacy, only historical data are available. As indicated
by Moertel in 1969, mild to moderate toxicity as objectively
calibrated by leukocytopenia seems to result in optimal response
to FU as well as its deoxyriboside FUDR (Moertel and Reiemeier,
1969; Ansfield, 1975). Apart from another small patient series
with rectal cancer undergoing preoperative radiochemotherapy
(Dahl et al, 1994), to our knowledge, no other conclusive data are
available about treatment tolerance as a potential prognostic
marker for response despite the fact that in 480% of all patients
receiving chemotherapy some kind of side effects (of course largely
depending on which chemotherapy regimen is administered) will
occur. Apart from use of inappropriate drug dosages in patients
with impaired renal or hepatic function, presence of well-defined
anticancer drug-specific risk factors such as DPD deficiency in
case of FU-based chemotherapy (Diasio et al, 1988, 1998; Johnson
et al, 1999; Milano et al, 1999), and to some extend gender (Stein
et al, 1995; Sloan et al, 2002) and age 465 (Stein et al, 1995;
Cascinu et al, 1996; Chiara et al, 1998; Popescu et al, 1999), the
reason/mechanism is still unclear which predisposes patients to
experience chemotherapy-related side effects.
As a result of uncertainties of a correlation between incidence
rates and severity of side effects with the effectiveness of palliative
chemotherapy in colorectal cancer, particularly as it concerns the
novel more effective combination regimens, the present study was
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sperformed. In an attempt to answer this potentially important
basic question, we have analysed the toxicity, objective response
and survival data of 303 patients with advanced colorectal cancer
who were consecutively treated in four prospective oxaliplatin- or
irinotecan-based combination chemotherapy studies.
PATIENTS AND METHODS
Patients
A total of 303 patients with advanced colorectal cancer, who
were entered in four different multicentre first- or second-line
chemotherapy protocols between 1998 and 2001 were analysed
(Scheithauer et al, 2001a,b,c, 2003). All patients had histologically
confirmed metastatic or locally advanced/recurrent adenocarcino-
mas with bidimensionally measurable disease (defined as presence
of at least one index lesion capable of two-dimensional measure-
ment by computed tomography (CT) scan. Additional eligibility
criteria in all four trials included age between 19 and 75 years, a
World Health Organisation (WHO) performance status of two
or less, and adequate bone marrow reserve, as well as renal and
hepatic function. Adjuvant 5-FU-based chemotherapy and/or
radiation was allowed if it was completed X6 months before
study entry. Within 2 weeks prior to initiating chemotherapy, all
patients were assessed by physical examination, routine haemato-
logy and biochemistry analyses and CT-scans (or MRI) to define
the extent of disease. Complete blood cell counts with platelet and
differential counts were repeated weekly, and serum chemistries
were determined at least once every course. All side effects,
performance status, body weight, physical examination and
subjective symptoms were recorded before each treatment course.
Target lesions were reassessed by CT-scan or MRI every 8–12
weeks; objective response was evaluated according to WHO
standard criteria.
Chemotherapy
The following six treatment regimens were administered to the 303
patients, who actively participated in four different trials: The first
trial was a phase II study of front-line combination chemotherapy
with raltitrexed 3mgm
 2 and oxaliplatin 130mgm
 2 both
administered on day 1 every 3 weeks (Scheithauer et al, 2001a).
In the second trial, the same dose regimen was administered to
patients failing prior fluoropyrimidine/LV-based chemotherapy
(Scheithauer et al, 2001b). The third trial was a randomised
multicentre phase II trial of oxaliplatin plus irinotecan vs
raltitrexed as first-line treatment with a crossover design upon
progression (Scheithauer et al, 2001c): patients randomised to the
combination arm, were treated with oxaliplatin 85mgm
 2 and
irinotecan 175mgm
 2 every 2 weeks. Patients randomised to the
raltitrexed-arm received a dose of 3mgm
 2 given on day 1 every 3
weeks. The last trial was also a randomised multicentre phase II
study of two different schedules of capecitabine plus oxaliplatin as
first-line treatment in advanced colorectal cancer (Scheithauer
et al, 2003). Half of the patients received oxaliplatin 130mgm
 2 on
day 1 plus capecitabine 2000mgmday on days 1–14 every 3
weeks, in the other treatment arm patients received oxaliplatin
85mgm
 2 on days 1 and 14 combined with capecitabine
3500mgm
 2day on days 1–7 and 14–21 every 4 weeks.
Side effects
Only chemotherapy-associated adverse reactions that occurred
during the first 3 months of treatment were analysed. This was
performed because (1) acute side effects generally occur within the
first few courses, and (2) to avoid a possible selection bias by
analysing fewer treatment courses in unresponsive patients. All
except five patients received a minimum of 3 months chemotherapy
(98.3%). Out of this five patients, two had a progressive disease
after 2 months, two experienced severe toxicities and one patient
refused further treatment after the first cycle of chemotherapy.
Oxaliplatin-associated sensory neuropathy, which is cumulative
in its nature, was not included in this analysis. Adverse events
were graded according to WHO standard toxicity criteria. All side
effects were first analysed in total, and then subdivided into
haematological and nonhaematological side effects, as well as
severe (grade 3/4) and minor (grade p2) toxicities.
Statistical analyses
Continuous covariates are described with mean and s.d. in the
case of normally distributed data and with median, minimum and
maximum for skewed covariates. Categorical variables are
described with frequencies and percentages. Differences between
the two interesting groups (complete remission (CR), partial
remission (PR) and stable disease (SD) vs progressive disease
(PD)) in terms of number of side effects, number of tumour sites,
gender, age and chemotherapy regimen were examined with
univariate and multiple logistic regression models always model-
ling the probability of experiencing CR; PR or SD vs PD. Number
of side effects and all other categorisations of side effects
(haematological and nonhaematological , WHO grade 42 and
WHO grade p2) as well as number of tumour sites are modelled as
linear factors in logistic regression analyses, implying a constant
odds ratio between consecutive variable values. All other
scrutinised factors are taken into account as categorical variables,
whereas categories male in case of gender, regimen, irinotecan
plus oxaliplatin for chemotherapy, and age up to 65 years served
as reference categories. All analyses were carried out using the
statistical software package SAS (version 8.02, SAS Institute, Cary,
NC, USA), P-values are two-sided and Po0.05 was considered
statistically significant.
RESULTS
A total of 303 patients (190 men and 113 women) who received
first- or second-line chemotherapy for advanced colorectal cancer
in four different clinical trials between 1998 and 2001 were
included in this analysis. The pretreatment characteristics of the
study population(s) which were essentially similar across the four
trials are summarised in Table 1. Patients were divided into two
groups: the first group (group I) had a positive treatment effect,
which included complete response, partial response and SD; the
second group (group II) was rated progressive during chemo-
therapy. As shown in Table 2, out of the 303 patients, 245 were
categorised in group I, and 58 patients in group II.
Out of the entire study population only six patients had no side
effects, and 297 patients had experienced at least one adverse
event. The median number of side effects (haematological and
nonhaematological, all WHO grades) in group I was 6 (range, 0–
12) compared to 4 (range, 0–13) in case of treatment failure.
The chance to have CR, PR or SD, in fact, was noted to be
increasing with an increasing number of side effects (OR¼1.342,
Po0.0001). Specifically, one additional side effect increases the
odds of no PD by 34% (Table 3). The increasing incidence of side
effects from PD to complete response showed a highly significant
correlation (Po0.0001) without overlapping 95% confidence
intervals from PD to SD onwards.
The observation of an inverse correlation of disease control with
treatment tolerance was confirmed when side effects were analysed
according to severity: in patients experiencing minor toxicities
(WHO grade p2; n¼284), the median number of side effects was
3 (range, 0–10) in case of treatment efficacy, and 2 (range, 0–7) in
nonresponders. The corresponding odds ratio in a univariate
logistic regression model was statistically significant (OR¼1.319,
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sP¼0.002). In patients with severe toxicities (WHO grade 42;
n¼45), responders had a median number of 2 side effects (range,
0–9), whereas nonresponder only suffered from 1 (range, 0–7;
OR¼1.372, P¼0.0006).
We then divided treatment-associated side effects into haema-
tological and nonhaematological. In all, 252 patients (83%) had
haematological side effects and 289 patients (95%) had at least one
nonhaematological side effect. Patients with at least SD had
significantly more (P¼0.0005) haematological side effects (median
3, range 0–4) than patients with tumour progression (median 1,
range 0–4). One haematological side effect more implies a 1.472
times higher odds to experience at least SD (P¼0.0005). The most
common nonhaematological side effects (apart from the cumula-
tive oxaliplatin-associated peripheral sensory neuropathy, which
was excluded from this analysis), were diarrhoea, transient
elevation of liver functional parameters and nausea/emesis. The
median number of nonhaematological side effects of a responder
were 4 (range, 0–9) vs 2 (range, 0–9) in case of treatment failure, a
difference that was again statistically significant (Po0.0001, OR:
1.40).
We subsequently analysed the correlation of the response status
and side effects according to the various treatment regimens
(Table 2). Of the patients (87% ) who received chemotherapy with
oxaliplatin plus capecitabine were in group I (80 patients), and
13% (12 patients) had PD (group II). The median number of side
effects in both groups was 6 (group I: range, 0–11; group II: range,
2–8): no difference was noted between the two groups for this
particular combination regimen (P¼0.578, OR: 1.07). In all, 82 out
Table 1 Selected pretreatment characteristics of the analyzed study
population
No of patients, n (%)
Gender
Male 190 63%
Female 113 37%
Age
Median 66.5
Range 38–79
WHO performance status
0 138 46%
1 123 40%
2 42 14%
Primary site
Colon 193 64%
Rectum 110 36%
Sites of metastases
Liver 218
Lung 75
Abdominopelvic mass 99
Other 118
Number of metastatic sites
Single 116 38%
Multiple 187 62%
Table 2 Descriptive statistics
Response to Treatment
CR+PR+SD vs PD
(n¼245) (n¼58) Total (n¼303)
Gender
Female 88 (77.9%) 25 (22.1%) 113
Male 157 (82.6%) 33 (17.4%) 190
Age
Up to 65 years 127 (79.4%) 33 (20.6%) 160
Older than 65 years 118 (82.5%) 25 (17.5%) 143
Mean (7s.d.) 63.12 (79.70) 62.05 (79.93) 62.92 (79.74)
Min–max 37–79 38–77 37–79
Number of side effects
Median (min–max) 6 (0–12) 4 (0–13) 6 (0–13)
Number of side effects WHO-grade o 2( n¼284)
Median (min–max) 3 (0–10) 2 (0–7) 3 (0–10)
Number of side effects WHO-gradeX2( n¼45)
Median (min–max) 2 (0–9) 1 (0–7) 2 (0–9)
Number of haematological side effects (n¼252)
Median (min–max) 3 (0–4) 1 (0–4) 2 (0–4)
Number of non-haematological side effects (n¼289)
Median (min–max) 4 (0–9) 2 (0–9) 3 (0–9)
Number of tumour sites
Median (min–max) 2 (1–5) 2 (1–5) 2 (1–5)
Chemotherapy regimen
Capecitabine plus oxaliplatin 80 (87.0%) 12 (13.0%) 92
Raltitrexed plus oxaliplatin 82 (91.1%) 8 (8.9%) 90
Irinotecan plus oxaliplatin 53 (82.8%) 11 (17.2%) 64
Raltitrexed 30 (52.6%) 27 (47.4%) 57
CR¼complete response, PR¼partial response, SD¼stable disease, PD¼progressive disease according to the World Health Organisation standard criteria.
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sof 90 patients (91%) who received raltitrexed plus oxaliplatin had
an objective response or SD, and eight patients had PD. The
median number of side effects in group I was 5 compared with
3.5 in group II, again a difference that did not reach the level of
statistical significance (P¼0.0623, OR: 1.46). A total of 64 patients
with metastatic colorectal cancer were treated with irinotecan plus
oxaliplatin as first-line therapy. Of these patients, 83% were
categorised in group I, and 11 patients in group II. In group I the
median number of side effects was 8 as opposed to group II, where
patients experienced a median number of 6 side effects (P¼0.028,
OR: 1.4). In all, 57 patients received raltitrexed as first-line
chemotherapy. The median number of side effects was 5 in group I
(n¼30), and in group II (n¼27) the median number of side
effects was 3 (P¼0.0038, OR: 1.46).
The median survival of all patients who had at least a stable
disease was 19 months compared to 5.5 months in those with PD.
When median survival was analysed according to the number
of adverse events, it was 10 (95%CI, 3–7), 16 (14–18), and 18
(16–20) months in case of 0–1, 2–5 and X6 AEs, respectively
(log-rank test: P¼0.01; Figure 1).
As indicated in Table 4, a multiple logistic regression model was
used to assess the partial effects of number of side effects, number
of tumour sites, gender, age and chemotherapy regimen in terms
of treatment benefit. The number of side effects (Po0.0001), the
number of tumour sites (P¼0.003), and treatment with raltitrexed
plus oxaliplatin (P¼0.0081) turned out to be significant prog-
nostic factors. As it concerns gender and age, no statistical
difference was seen neither in the univariate nor in the multi-
variable analysis.
DISCUSSION
Administration of the same dose regimen of a specific anticancer
drug or drug combination to a population of patients is likely
to result in considerable variations of toxicities ranging from no
side effect to potentially lethal events (Kuilenburg et al, 2001;
Rothenberg et al, 2001). In our univariate and multivariable
analyses the number of side effects associated with modern
combination chemotherapy in advanced colorectal cancer turned
out to be a significant independent prognostic factor; one
additional adverse reaction, in fact, seems to increase the odds
of response or SD by 34%. Similarly, occurrence of side effects was
found to correspond with an improved overall survival. The
correlation between toxicity and therapeutic benefit was noted
irrespective of the degree and type of toxicity, that is, nonhaema-
tological vs haematological. The latter observation seems impor-
tant because haematological side effects are objectively measured
toxicity parameters, which are not subject to a potential reporting
bias. Variations of the correlation between toxicity and therapeutic
benefit between the four treatment regimens are most likely to be
related to the rather small study patient populations analysed, and
especially the low rate of treatment failures in case of combination
chemotherapy; this hypothesis is supported by the largest
correlation of adverse events and response noted in the (least
effective) raltitrexed control group in one of the studies.
It seems noteworthy that the correlation between toxicity and
therapeutic benefit was not affected by gender and age. Differences
in reporting subjective symptoms between men and women have
been described in an analysis of 2448 patients who received FU-
based chemotherapy for colorectal cancer (Sloan et al, 2002).
Women experience toxicity more frequently and with more
severity than men, whereby the gender variation could be related
to the methylenetetrahydrofolate reductase C677T polymorphism
(Van Rijnsoever et al, 2002), and/or the different levels of
dihydropyrimidine dehydrogenase (Diasio, 1998; Milano et al,
1999). The current analysis also shows no difference between sexes
in objective response rate or survival. The same is true for various
otherwise rather divergent data about age and toxicity (Stein et al,
1995; Cascinu et al, 1996; Chiara et al, 1998; Popescu et al, 1999).
Response and survival were not affected in these studies as they
were in the current study, regardless of a difference in tolerance of
5-FU-based therapy between younger and older patients.
The results of our findings with the use of modern combination
chemotherapy in advanced colorectal cancer are in agreement with
an analysis of the relationship between the toxicity of FU (n¼176)
and FUDR monotherapy (n¼203) to objective response rates in
a comparable study population, which was published in 1969
(Moertel and Reiemeier, 1969). Fluoropyrimidine treatment to
the point of mild or moderate leukocytopenia (1500–4500)
resulted in a response rate of 22.7 vs 8.7 and 15% in case of no
Table 3 Univariate logistic regression analyses
Odds ratio 95% CI P
Number of side effects 1.342 1.186–1.519 o0.0001
Number of side effects WHO grade 2 1.319 1.107–1.572 0.0020
Number of side effects WHO grade 42 1.372 1.146–1.642 0.0006
Number of haematological side effects 1.472 1.183–1.832 0.0005
Number of nonhaematological side effects 1.398 1.182–1.654 o0.0001
Gender (reference group: male) 0.740 0.414–1.323 0.3099
Age (reference group: up to 65 years) 1.226 0.689–2.184 0.4880
Number of tumour sites 0.595 0.428–0.828 0.0021
Table 4 Multiple logistic regression analysis
Odds Ratio 95 % CI P
Number of side effects 1.349 1.167–1.559 o0.0001
Gender (reference group: male) 0.715 0.357–1.433 0.3439
Age (reference group: up to 65 years) 1.556 0.799–3.033 0.1939
Number of tumour sites 0.570 0.394–0.826 0.0030
Chemotherapy regimen
Irinotecan plus oxaliplatin 1.000
Raltitrexed plus oxaliplatin 4.271 1.457–12.521 0.0081
Raltitrexed 0.526 0.198–1.395 0.1966
Capecitabine plus oxaliplatin 1.697 0.654–4.406 0.2770
Months
70 60 50 40 30 20 10 0
1.0
0.8
0.6
0.4
0.2
0.0
Number of AE
> 5
2−5
0−1
P < 0.01
Figure 1 Median survival according to number of adverse events.
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evaluation of a planned subtoxic FU dosage conducted by the
Central Oncology Group has also demonstrated a significant
inferiority in response rate when compared to a dose-producing
mild to moderate toxicity (Ansfield, 1975). A third analysis we could
identify in terms of correlating side effects with tumour response
was published by Dahl et al (1994). The investigators described 159
patients who were treated with preoperative radiotherapy (31.5Gy
in 18 fractions) for potentially resectable rectal adenocarcinoma.
Patients were examined for a possible relationship between bowel
toxicity manifested as diarrhoea and tumour size in the operative
specimen as well as recurrence rate. Patients who required drugs
for diarrhoea had significantly smaller tumours at surgery (2.5 vs
3.5cm). Furthermore, patients without significant radiation-induced
diarrhoea had more recurrences (37.5 vs 14.3%). The disease-
specific survival rate was also significantly better (P¼0.02) at 1.5
and 10 years in patients with diarrhoea WHO grades 3 and 4. It was
therefore concluded that a correlation between bowel sensitivity and
tumour sensitivity to radiation might exist.
In conclusion, the results of this analysis of over 300 patients
with advanced colorectal cancer suggest that occurrence of
side effects during modern combination chemotherapy in
advanced colorectal cancer is an independent prognostic indica-
tor of response. Although these data might have to be confirmed
for more commonly used fluoropyrimidine combination regimens
(such as FOLFOX or FOLFIRI) the correct interpretation of
the present and the few other available corresponding results
would already be available: as perfectly articulated by Moertel
in the fluoropyrimidine monotherapy era about 35 years ago:
‘To achieve the most favourable results you must play the
piper, but not too much’ (Moertel and Reiemeier, 1969). Patients
should receive adequate drug dosages, which may warrant
individualised dose escalations. At no price, however, treatment-
associated side effects should be too severe and thus interfere
with the patients’ quality-of-life. As demonstrated in recent trials,
dose reductions in patients experiencing severe toxicity do
not lead to compromised efficacy (Cassidy et al, 2002; Blum
et al, 2001).
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